JP2022530404A5 - - Google Patents
Info
- Publication number
- JP2022530404A5 JP2022530404A5 JP2021562979A JP2021562979A JP2022530404A5 JP 2022530404 A5 JP2022530404 A5 JP 2022530404A5 JP 2021562979 A JP2021562979 A JP 2021562979A JP 2021562979 A JP2021562979 A JP 2021562979A JP 2022530404 A5 JP2022530404 A5 JP 2022530404A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- antibody fragment
- fragment according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837214P | 2019-04-23 | 2019-04-23 | |
| US62/837,214 | 2019-04-23 | ||
| PCT/EP2020/060955 WO2020216697A1 (en) | 2019-04-23 | 2020-04-20 | Cd73 blocking antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530404A JP2022530404A (ja) | 2022-06-29 |
| JP2022530404A5 true JP2022530404A5 (enExample) | 2023-04-25 |
| JP7530913B2 JP7530913B2 (ja) | 2024-08-08 |
Family
ID=70456747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562979A Active JP7530913B2 (ja) | 2019-04-23 | 2020-04-20 | Ｃｄ７３遮断抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12528876B2 (enExample) |
| EP (1) | EP3959239A1 (enExample) |
| JP (1) | JP7530913B2 (enExample) |
| KR (1) | KR20220002959A (enExample) |
| CN (1) | CN113784981B (enExample) |
| AU (1) | AU2020260693A1 (enExample) |
| BR (1) | BR112021021224A2 (enExample) |
| CA (1) | CA3136698A1 (enExample) |
| IL (1) | IL286997A (enExample) |
| MX (1) | MX2021012769A (enExample) |
| SG (1) | SG11202111106WA (enExample) |
| TW (1) | TWI834867B (enExample) |
| WO (1) | WO2020216697A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204417B1 (en) | 2014-10-10 | 2020-07-22 | Innate Pharma | Cd73 blockade |
| BR112020006809A2 (pt) * | 2017-10-06 | 2020-10-06 | Innate Pharma | anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso |
| TW202135823A (zh) | 2020-01-03 | 2021-10-01 | 美商英塞特公司 | Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法 |
| PE20221409A1 (es) | 2020-01-03 | 2022-09-20 | Incyte Corp | Anticuerpos anti-cd73 y usos de estos |
| KR20230050378A (ko) * | 2020-08-13 | 2023-04-14 | 이나뜨 파르마 에스.에이. | 항-cd73 항체를 사용하여 암을 치료하는 방법 |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ATE483472T1 (de) | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| US8961967B2 (en) | 2009-11-30 | 2015-02-24 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| EP3204417B1 (en) * | 2014-10-10 | 2020-07-22 | Innate Pharma | Cd73 blockade |
| US20180030144A1 (en) | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
| AU2015349878A1 (en) * | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| US10736963B2 (en) | 2015-07-24 | 2020-08-11 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| CA3005986A1 (en) | 2015-11-23 | 2017-06-01 | Innate Pharma | Cd39 vascular isoform targeting agents |
| CN114805575B (zh) | 2015-12-09 | 2024-07-23 | 科尔沃斯制药股份有限公司 | 人源化抗cd73抗体 |
| CA3009484A1 (en) * | 2015-12-22 | 2017-06-29 | Abbvie Stemcentrx Llc | Novel anti-mmp16 antibodies and methods of use |
| EP3912681A1 (en) | 2016-03-14 | 2021-11-24 | Orega Biotech | Anti-cd39 antibodies |
| EP3577138A1 (en) | 2017-02-06 | 2019-12-11 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| IL269150B2 (en) | 2017-03-16 | 2025-04-01 | Innate Pharma | Cancer treatment preparations and methods |
| BR112020006809A2 (pt) | 2017-10-06 | 2020-10-06 | Innate Pharma | anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso |
| KR102781619B1 (ko) | 2017-11-15 | 2025-03-14 | 이나뜨 파르마 에스.에이. | 암의 치료를 위한 인간 CD39 단백질의 ATPase 활성을 결합 및 저해하는 항체 |
| EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| DK3807316T3 (da) | 2018-06-18 | 2024-07-29 | Innate Pharma | Sammensætninger og fremgangsmåder til behandling af cancer |
| KR20230050378A (ko) | 2020-08-13 | 2023-04-14 | 이나뜨 파르마 에스.에이. | 항-cd73 항체를 사용하여 암을 치료하는 방법 |
-
2020
- 2020-04-20 MX MX2021012769A patent/MX2021012769A/es unknown
- 2020-04-20 BR BR112021021224A patent/BR112021021224A2/pt unknown
- 2020-04-20 CN CN202080030003.3A patent/CN113784981B/zh active Active
- 2020-04-20 AU AU2020260693A patent/AU2020260693A1/en active Pending
- 2020-04-20 EP EP20721175.6A patent/EP3959239A1/en active Pending
- 2020-04-20 SG SG11202111106WA patent/SG11202111106WA/en unknown
- 2020-04-20 JP JP2021562979A patent/JP7530913B2/ja active Active
- 2020-04-20 CA CA3136698A patent/CA3136698A1/en active Pending
- 2020-04-20 WO PCT/EP2020/060955 patent/WO2020216697A1/en not_active Ceased
- 2020-04-20 KR KR1020217036983A patent/KR20220002959A/ko active Pending
- 2020-04-23 TW TW109113576A patent/TWI834867B/zh active
-
2021
- 2021-10-05 IL IL286997A patent/IL286997A/en unknown
- 2021-10-22 US US17/451,835 patent/US12528876B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022530404A5 (enExample) | ||
| JP7854016B2 (ja) | 腫瘍治療薬及びその応用 | |
| JP2024167313A5 (enExample) | ||
| JP2022079549A5 (enExample) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2022093564A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2020515508A5 (enExample) | ||
| JP2021531254A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| JP2013056885A5 (enExample) | ||
| JP2018512175A5 (enExample) | ||
| JP2020514310A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| JP2024102055A5 (enExample) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| JP2011509245A5 (enExample) | ||
| JP2020500834A5 (enExample) | ||
| JP2020521478A5 (enExample) | ||
| JP2020517239A5 (enExample) | ||
| JP2011207882A5 (enExample) |